The efficacy of interactive group psychoeducation for children with leukaemia: A randomised controlled trial.
AuthorsDay, Marianne; email: email@example.com
Harris, Sally; email: firstname.lastname@example.org
Hussein, Deema; email: email@example.com
Saka, Mohamad Yassin; email: firstname.lastname@example.org
Stride, Chris; email: email@example.com
Jones, Myles; email: firstname.lastname@example.org
Makin, Guy; email: email@example.com
Rowe, Richard; email: firstname.lastname@example.org
MetadataShow full item record
AbstractTo evaluate an interactive group psychoeducation programme for children treated for leukaemia. A longitudinal randomised controlled study across four UK hospitals with an immediate (N = 26) and delay control group (N = 32). The intervention covered the pathophysiology of leukaemia, its treatment, side effects and the importance of positive health behaviours. Primary outcomes were parent-reported child health related quality of life (HRQoL) and behavioural difficulties. Secondary outcomes were child-reported HRQoL, cancer-specific HRQoL, child confidence, caregiver burden, and treatment anxiety. Measures were completed pre- and immediately post-intervention, and at 13 and 26-weeks follow-up. Change over time was analysed using multilevel modelling. Acceptability questionnaires rated the intervention on benefits, recommendations, and barriers to participation. The intervention significantly improved parent-reported child HRQoL but did not have a significant effect on other outcomes. Acceptability of the intervention was high. This study provides initial evidence that interactive group psychoeducation is acceptable to families and improves HRQoL in children with leukaemia. Difficulties with recruitment removed power to detect effect sizes that are plausible for psychoeducational interventions. Further studies to explore the potential of psychoeducation to improve outcomes for children with leukaemia and an examination of barriers to participation within this population are warranted. [Abstract copyright: Copyright © 2021 Elsevier B.V. All rights reserved.]
CitationPatient education and counseling
DescriptionFrom PubMed via Jisc Publications Router
History: received 2020-10-28, revised 2021-03-30, accepted 2021-04-22
Publication status: aheadofprint
Showing items related by title, author, creator and subject.
Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?Frizziero, Melissa; email: email@example.com; Durand, Alice; orcid: 0000-0002-0193-9058; email: firstname.lastname@example.org; Taboada, Rodrigo G.; orcid: 0000-0001-5674-2669; email: email@example.com; Zaninotto, Elisa; email: firstname.lastname@example.org; Luchini, Claudio; orcid: 0000-0003-4901-4908; email: email@example.com; Chakrabarty, Bipasha; email: firstname.lastname@example.org; Hervieu, Valérie; email: email@example.com; Claro, Laura C. L.; email: firstname.lastname@example.org; Zhou, Cong; orcid: 0000-0002-6938-4685; email: email@example.com; Cingarlini, Sara; email: firstname.lastname@example.org; et al. (MDPI, 2021-08-18)Extra-pulmonary neuroendocrine carcinomas (EP-NECs) are lethal cancers with limited treatment options. Identification of contributing factors to the observed heterogeneity of clinical outcomes within the EP-NEC family is warranted, to enable identification of effective treatments. A multicentre retrospective study investigated potential differences in “real-world” treatment/survival outcomes between small-cell (SC) versus (vs.) non-SC EP-NECs. One-hundred and seventy patients were included: 77 (45.3%) had SC EP-NECs and 93 (54.7%) had non-SC EP-NECs. Compared to the SC subgroup, the non-SC subgroup had the following features: (1) a lower mean Ki-67 index (69.3% vs. 78.7%; p = 0.002); (2) a lower proportion of cases with a Ki-67 index of ≥55% (73.9% vs. 88.7%; p = 0.025); (3) reduced sensitivity to first-line platinum/etoposide (objective response rate: 31.6% vs. 55.1%, p = 0.015; and disease control rate; 59.7% vs. 79.6%, p = 0.027); (4) worse progression-free survival (PFS) (adjusted-HR = 1.615, p = 0.016) and overall survival (OS) (adjusted-HR = 1.640, p = 0.015) in the advanced setting. Within the advanced EP-NEC cohort, subgroups according to morphological subtype and Ki-67 index (55% vs. ≥55%) had significantly different PFS (adjusted-p = 0.021) and OS (adjusted-p = 0.051), with the non-SC subgroup with a Ki-67 index of 55% and non-SC subgroup with a Ki-67 index of ≥55% showing the best and worst outcomes, respectively. To conclude, the morphological subtype of EP-NEC provides complementary information to the Ki-67 index and may aid identification of patients who could benefit from alternative first-line treatment strategies to platinum/etoposide.
Elevated Circulating and Placental SPINT2 Is Associated with Placental DysfunctionMurphy, Ciara N.; orcid: 0000-0001-6996-7250; email: email@example.com; Walker, Susan P.; email: firstname.lastname@example.org; MacDonald, Teresa M.; email: email@example.com; Keenan, Emerson; orcid: 0000-0003-1966-2293; email: firstname.lastname@example.org; Hannan, Natalie J.; email: email@example.com; Wlodek, Mary E.; orcid: 0000-0002-8490-9099; email: firstname.lastname@example.org; Myers, Jenny; email: Jenny.Myers@manchester.ac.uk; Briffa, Jessica F.; email: email@example.com; Romano, Tania; orcid: 0000-0002-8581-2256; email: firstname.lastname@example.org; Roddy Mitchell, Alexandra; email: email@example.com; et al. (MDPI, 2021-07-12)Biomarkers for placental dysfunction are currently lacking. We recently identified SPINT1 as a novel biomarker; SPINT2 is a functionally related placental protease inhibitor. This study aimed to characterise SPINT2 expression in placental insufficiency. Circulating SPINT2 was assessed in three prospective cohorts, collected at the following: (1) term delivery (n = 227), (2) 36 weeks (n = 364), and (3) 24–34 weeks’ (n = 294) gestation. SPINT2 was also measured in the plasma and placentas of women with established placental disease at preterm (34 weeks) delivery. Using first-trimester human trophoblast stem cells, SPINT2 expression was assessed in hypoxia/normoxia (1% vs. 8% O2), and following inflammatory cytokine treatment (TNFα, IL-6). Placental SPINT2 mRNA was measured in a rat model of late-gestational foetal growth restriction. At 36 weeks, circulating SPINT2 was elevated in patients who later developed preeclampsia (p = 0.028; median = 2233 pg/mL vs. controls, median = 1644 pg/mL), or delivered a small-for-gestational-age infant (p = 0.002; median = 2109 pg/mL vs. controls, median = 1614 pg/mL). SPINT2 was elevated in the placentas of patients who required delivery for preterm preeclampsia (p = 0.025). Though inflammatory cytokines had no effect, hypoxia increased SPINT2 in cytotrophoblast stem cells, and its expression was elevated in the placental labyrinth of growth-restricted rats. These findings suggest elevated SPINT2 is associated with placental insufficiency.
Evidence That a TRPA1-Mediated Murine Model of Temporomandibular Joint Pain Involves NLRP3 Inflammasome ActivationKodji, Xenia; email: firstname.lastname@example.org; Kee, Zizheng; email: email@example.com; McKenna, Robyn; email: firstname.lastname@example.org; de Sousa Valente, Joao; orcid: 0000-0003-1888-6324; email: email@example.com; Ravenscroft, Harriet; email: firstname.lastname@example.org; McMillan, Hayley; email: email@example.com; Gamble, John; email: firstname.lastname@example.org; Dombrowski, Yvonne; email: email@example.com; Moynagh, Paul; email: firstname.lastname@example.org; Brough, David; email: email@example.com; et al. (MDPI, 2021-10-23)This study investigates the role of transient receptor potential ankyrin 1 (TRPA1) in murine temporomandibular joint (TMJ) inflammatory hyperalgesia and the influence of the NLR family pyrin domain-containing 3 (NLRP3) inflammasome. Two distinct murine models of TMJ pain and inflammation (zymosan and CFA) were established. Spontaneous pain-like behaviours were observed as unilateral front paw cheek wipes. Ipsilateral cheek blood flow was used as a measure of ongoing inflammation, which, to our knowledge, is a novel approach to assessing real-time inflammation in the TMJ. Joint tissue and trigeminal ganglia were collected for ex vivo investigation. Both zymosan and CFA induced a time-dependent increase in hyperalgesia and inflammation biomarkers. Zymosan induced a significant effect after 4 h, correlating with a significantly increased IL-1β protein expression. CFA (50 µg) induced a more sustained response. The TRPA1 receptor antagonist A967079 significantly inhibited hyper-nociception. The NLRP3 inhibitor MCC950 similarly inhibited hyper-nociception, also attenuating inflammatory markers. In the trigeminal ganglia, CFA-induced CGRP expression showed trends of inhibition by A967079, whilst lba1 immunofluorescence was significantly inhibited by A967079 and MCC950, where the effect of TRPA1 inhibition lasted up to 14 days. Our results show that stimulation of TRPA1 is key to the TMJ pain. However, the inflammasome inhibitor exhibited similar properties in attenuating these pain-like behaviours, in addition to some inflammatory markers. This indicates that in addition to the therapeutic targeting of TRPA1, NLRP3 inhibition may provide a novel therapeutic strategy for TMJ inflammation and pain.